Search Results

Welldoc Receives 10th 510(k) Clearance from FDA for Award-Winning Diabetes Platform BlueStar.

Welldoc®, a digital health leader revolutionizing chronic care, today announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar®.

Welldoc Granted 31st Patent for First-in-Class Chronic Care Platform.

CCS has announced a new technology partnership Welldoc and ZeOmega to expand its established LivingConnected® solution.

Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin solutions, currently in development.

Welldoc, a trailblazer in digital health that is revolutionizing chronic condition management, and Dexcom, the leader in real-time continuous glucose monitoring (CGM), today announced the first customer for a new integrated offering to drive improved health for people with Type 2 diabetes. Welldoc will offer its BlueStar ® digital health

Welldoc, announced today a collaboration with Dexcom, the global leader in continuous glucose monitoring (CGM) systems for people with diabetes.

Feb. 25, 2020 14:00 UTC Welldoc and Redox Partner to Optimize Provider Interaction with Chronic Disease Management Platform Partnership ensures bidirectional integration with EHRs and insights available at the point of care MADISON, Wis.--( BUSINESS WIRE )-- Welldoc , a leading digital health company revolutionizing chronic disease management, announced today its strategic partnership with Redox Inc. , the leading interoperability platform for healthcare data exchange.

Validic, and Welldoc announced their partnership to broaden the access and integration of personal health data within the Welldoc BlueStar® platform.

This is Welldoc’s 8th 510(k) filing to the U.S. Food and Drug Administration